Dong-Yun He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Dong-Yun He has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Bao-Rong Chi
The First Hospital of Jilin University
1 shared publication- Chang Li
State Key Laboratory of Pathogen and Biosecurity, Key Laboratory of Jilin Province for Zoonoses Prevention and Control, Academy of Military Medical Sciences, Changchun 130122, China
1 shared publication - Haihong Yang
Department of Thoracic Oncology, The First Affiliated Hospital, Guangzhou Medical University, State Key Laboratory of Respiratory Diseases, National Clinical Research Center of Respiratory Disease, Guangzhou, China
1 shared publication - Hongyu Wang
Department of Vascular Medicine, Peking University Shougang Hospital, Jinyuanzhuang Road 9, Shijingshan District, Beijing 100144, PR China
1 shared publication - Huifan Ji
Department of Hepatology, The First Hospital of Jilin University, Changchun, China
1 shared publication - Kai Wang
Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children’s Hospital of Philadelphia, Philadelphia, USA
1 shared publication
Latest Publications
- Open Access
- 31 October 2022
- Published by Hindawi Limited in Canadian Respiratory Journal
- Vol. 2022, 1-5
Efficacy of Intrapleural or Intrapericardial Injection of Single Bevacizumab in the Treatment of Lung Cancer-Mediated Malignant Effusion
The usage of bevacizumab for malignant pleural effusion (MPE) or malignant pericardial effusion (MPCE) has attracted increasing interest from researchers, but the precise ways of bevacizumab administration remain unknown. Patients with histologically or cytologically confirmed non-small-cell lung cancer (NSCLC) with MPE or MPCE were enrolled in the study and treated with a low dose of single bevacizumab (100 mg) intrapleurally or intrapericardially injected after the drainage of the effusions. The Lung Cancer Symptom Scale (LCSS), efficacy, and safety of drug administration were used as evaluation parameters in this study. The results indicated that lung cancer-related symptoms were significantly improved following treatment, compared with symptoms before the treatment (LCSS, score 494 ± 78 vs. score 377 ± 77, mean ± SD) ( ). Malignant effusions were well controlled, and the median time to progression (TTP) was 91 days and 111 days in MPE and MPCE, respectively. In addition, no severe side effects were observed, except in one patient with mild dizziness. In summary, the low dose of single bevacizumab (100 mg) with intrapleural or intrapericardial injection is effective and safe in the treatment of lung cancer-mediated malignant effusion, rapidly improving the malignant effusion-related symptoms and quality of life in patients with NSCLC.
- 31 October 2022
- Published by Hindawi Limited in Canadian Respiratory Journal
- Vol. 2022, 1-5
Open AccessEfficacy of Intrapleural or Intrapericardial Injection of Single Bevacizumab in the Treatment of Lung Cancer-Mediated Malignant Effusion
The usage of bevacizumab for malignant pleural effusion (MPE) or malignant pericardial effusion (MPCE) has attracted increasing interest from researchers, but the precise ways of bevacizumab administration remain unknown. Patients with histologically or cytologically confirmed non-small-cell lung cancer (NSCLC) with MPE or MPCE were enrolled in the study and treated with a low dose of single bevacizumab (100 mg) intrapleurally or intrapericardially injected after the drainage of the effusions. The Lung Cancer Symptom Scale (LCSS), efficacy, and safety of drug administration were used as evaluation parameters in this study. The results indicated that lung cancer-related symptoms were significantly improved following treatment, compared with symptoms before the treatment (LCSS, score 494 ± 78 vs. score 377 ± 77, mean ± SD) ( ). Malignant effusions were well controlled, and the median time to progression (TTP) was 91 days and 111 days in MPE and MPCE, respectively. In addition, no severe side effects were observed, except in one patient with mild dizziness. In summary, the low dose of single bevacizumab (100 mg) with intrapleural or intrapericardial injection is effective and safe in the treatment of lung cancer-mediated malignant effusion, rapidly improving the malignant effusion-related symptoms and quality of life in patients with NSCLC.
- 28 March 2013
- Published by Springer Nature in Chemical Research in Chinese Universities
- Vol. 29 (2) , 270-274
Antitumor effects of Newcastle disease virus hemagglutinin-neuraminidase used as a molecular adjuvant
- 28 March 2013
- Published by Springer Nature in Chemical Research in Chinese Universities
- Vol. 29 (2) , 270-274
Antitumor effects of Newcastle disease virus hemagglutinin-neuraminidase used as a molecular adjuvant